The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
Clinical Development of BRAF plus MEK Inhibitor Combinations
Open accessAbstract
Genomic profiling shows that many solid tumors are characterized by specific driver aberrations, and this has expanded the therapeutic options for many patients. The mitogen-activated protein kinase (MAPK) pathway is a key cell signaling pathway involved in regulating cellular growth, proliferation, and survival. Driver mutations in the BRAF gene, a key player in the MAPK pathway, are described in multiple tumor types, including subsets of melanoma, non-small cell lung cancer (NSCLC), and anaplastic thyroid cancer (ATC), making BRAF a desirable target for inhibition. BRAF inhibitors have shown efficacy in several cancers; however, most patients eventually develop resistance. To delay or prevent resistance, combination therapy targeting BRAF and MEK, a downstream signaling target of BRAF in the MAPK pathway, was evaluated and demonstrated synergistic benefit. BRAF and MEK inhibitor combinations have been approved for use in various cancers by the US FDA. We review the clinical data for various BRAF plus MEK combination regimens in three cancer types with underlying BRAF driver mutations: melanoma, NSCLC, and ATC. We also discuss practical treatment considerations and management of selected combination therapy toxicities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationHauschild, A., Grob, J.-J., Demidov, L. V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C. U., Miller, W. H., Kaempgen, E., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60868-x · Cited by 2,989
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Gershenwald, J. E., Scolyer, R. A., Hess, K. R., Sondak, V. K., Long, G. V., Ross, M. I., Lazar, A. J., Faries, M. B., Kirkwood, J. M., McArthur, G. A., et al. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21409 · Cited by 2,283
Self-citationMelanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., Chen, Z., Lee, M.-K., Attar, N., Sazegar, H., et al. (2010) · Nature · doi:10.1038/nature09626 · Cited by 2,192
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406037 · Cited by 1,899
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764
Self-citationRAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,622
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
Long, G. V., Hauschild, A., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., Haydon, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708539 · Cited by 1,490
Self-citationHodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30700-9 · Cited by 1,399
Long, G. V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Grob, J.-J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60898-4 · Cited by 1,399
Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma
Robert, C., Grob, J. J., Stroyakovskiy, D., Karaszewska, B., Hauschild, A., Levchenko, E., Chiarion Sileni, V., Schachter, J., Garbe, C., Bondarenko, I., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904059 · Cited by 1,389
Planchard, D., Smit, E. F., Groen, H. J. M., Mazieres, J., Besse, B., Helland, Å., Giannone, V., D'Amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,360
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
Tsai, J., Lee, J. T., Wang, W., Zhang, J., Cho, H., Mamo, S., Bremer, R., Gillette, S., Kong, J., Haass, N. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711741105 · Cited by 1,346
Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
Landa, I., Ibrahimpasic, T., Boucai, L., Sinha, R., Knauf, J. A., Shah, R. H., Dogan, S., Ricarte-Filho, J. C., Krishnamoorthy, G. P., Xu, B., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85271 · Cited by 1,284
Villanueva, J., Vultur, A., Lee, J. T., Somasundaram, R., Fukunaga-Kalabis, M., Cipolla, A. K., Wubbenhorst, B., Xu, X., Gimotty, P. A., Kee, D., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.023 · Cited by 1,259
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
BRAF and RAS mutations in human lung cancer and melanoma.
Brose, M. S., Volpe, P., Feldman, M. D., Kumar, M. S., Rishi, I., Gerrero, R. M., Einhorn, E., Herlyn, M., Minna, J. D., Nicholson, A. G., et al. (2002) · PubMed · Cited by 1,048
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038
Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30142-6 · Cited by 1,037
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Ascierto, P. A., McArthur, G. A., Dréno, B., Atkinson, V., Liszkay, G., Di Giacomo, A. M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30122-x · Cited by 1,022
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
Frederick, D. T., Piris, A., Cogdill, A. P., Cooper, Z. A., Lezcano, C., Ferrone, C. R., Mitra, D., Boni, A., Newton, L. P., Liu, C., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1630 · Cited by 944
Subbiah, V., Kreitman, R. J., Wainberg, Z. A., Cho, J. Y., Schellens, J. H. M., Soria, J. C., Wen, P. Y., Zielinski, C., Cabanillas, M. E., Urbanowitz, G., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.6785 · Cited by 892
Self-citationPlanchard, D., Besse, B., Groen, H. J. M., Souquet, P.-J., Quoix, E., Baik, C. S., Barlesi, F., Kim, T. M., Mazieres, J., Novello, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30146-2 · Cited by 888
Self-citationGilliland, F. D., Hunt, W. C., Morris, D. M., & Key, C. R. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970201)79:3<564::aid-cncr20>3.0.co;2-0 · Cited by 803
Davies, M. A., Saiag, P., Robert, C., Grob, J.-J., Flaherty, K. T., Arance, A., Chiarion-Sileni, V., Thomas, L., Lesimple, T., Mortier, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30429-1 · Cited by 766
Boni, A., Cogdill, A. P., Dang, P., Udayakumar, D., Njauw, C.-N. J., Sloss, C. M., Ferrone, C. R., Flaherty, K. T., Lawrence, D. P., Fisher, D. E., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0118 · Cited by 742
The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells
Sumimoto, H., Imabayashi, F., Iwata, T., & Kawakami, Y. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051848 · Cited by 698
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697
NRAS mutation status is an independent prognostic factor in metastatic melanoma
Jakob, J. A., Bassett, R. L., Ng, C. S., Curry, J. L., Joseph, R. W., Alvarado, G. C., Rohlfs, M. L., Richard, J., Gershenwald, J. E., Kim, K. B., et al. (2012) · Cancer · doi:10.1002/cncr.26724 · Cited by 689
Anaplastic thyroid carcinoma: Treatment outcome and prognostic factors
Kebebew, E., Greenspan, F. S., Clark, O. H., Woeber, K. A., & McMillan, A. (2005) · Cancer · doi:10.1002/cncr.20936 · Cited by 666
Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
Wilmott, J. S., Long, G. V., Howle, J. R., Haydu, L. E., Sharma, R. N., Thompson, J. F., Kefford, R. F., Hersey, P., & Scolyer, R. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2479 · Cited by 652
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
Eisen, T., Ahmad, T., Flaherty, K. T., Gore, M., Kaye, S., Marais, R., Gibbens, I., Hackett, S., James, M., Schuchter, L. M., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603291 · Cited by 644
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Corcoran, R. B., André, T., Atreya, C. E., Schellens, J. H. M., Yoshino, T., Bendell, J. C., Hollebecque, A., McRee, A. J., Siena, S., Middleton, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1226 · Cited by 592
Dummer, R., Ascierto, P. A., Gogas, H. J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30497-2 · Cited by 588
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF V600E melanoma
Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E. M., Koya, R. C., Graeber, T. G., Comin-Anduix, B., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4691 · Cited by 563
Prognostic factors for survival in melanoma patients with brain metastases
Davies, M. A., Liu, P., McIntyre, S., Kim, K. B., Papadopoulos, N., Hwu, W., Hwu, P., & Bedikian, A. (2011) · Cancer · doi:10.1002/cncr.25634 · Cited by 548
Hauschild, A., Agarwala, S. S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7636 · Cited by 548
Self-citationPlanchard, D., Kim, T. M., Mazieres, J., Quoix, E., Riely, G., Barlesi, F., Souquet, P.-J., Smit, E. F., Groen, H. J. M., Kelly, R. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00077-2 · Cited by 453
Yang, H., Higgins, B., Kolinsky, K., Packman, K., Go, Z., Iyer, R., Kolis, S., Zhao, S., Lee, R., Grippo, J. F., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0646 · Cited by 407
Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing
Kunstman, J. W., Juhlin, C. C., Goh, G., Brown, T. C., Stenman, A., Healy, J. M., Rubinstein, J. C., Choi, M., Kiss, N., Nelson-Williams, C., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddu749 · Cited by 364
Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
Welsh, S. J., & Corrie, P. G. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014566428 · Cited by 341
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma
Ascierto, P. A., Ferrucci, P. F., Fisher, R., Del Vecchio, M., Atkinson, V., Schmidt, H., Schachter, J., Queirolo, P., Long, G. V., Di Giacomo, A. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0448-9 · Cited by 324
Johnson, D. B., Menzies, A. M., Zimmer, L., Eroglu, Z., Ye, F., Zhao, S., Rizos, H., Sucker, A., Scolyer, R. A., Gutzmer, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.08.022 · Cited by 323
Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
Paraiso, K. H. T., Fedorenko, I. V., Cantini, L. P., Munko, A. C., Hall, M., Sondak, V. K., Messina, J. L., Flaherty, K. T., & Smalley, K. S. M. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605714 · Cited by 314
Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
Ugurel, S., Röhmel, J., Ascierto, P. A., Flaherty, K. T., Grob, J. J., Hauschild, A., Larkin, J., Long, G. V., Lorigan, P., McArthur, G. A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.028 · Cited by 287
Chapman, P. B., Robert, C., Larkin, J., Haanen, J. B., Ribas, A., Hogg, D., Hamid, O., Ascierto, P. A., Testori, A., Lorigan, P. C., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx339 · Cited by 262
Hauschild, A., Dummer, R., Schadendorf, D., Santinami, M., Atkinson, V., Mandalà, M., Chiarion-Sileni, V., Larkin, J., Nyakas, M., Dutriaux, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01219 · Cited by 256
Self-citationRheault, T. R., Stellwagen, J. C., Adjabeng, G. M., Hornberger, K. R., Petrov, K. G., Waterson, A. G., Dickerson, S. H., Mook, R. A., Laquerre, S. G., King, A. J., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000063 · Cited by 253
Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
Lacouture, M. E., Duvic, M., Hauschild, A., Prieto, V. G., Robert, C., Schadendorf, D., Kim, C. C., McCormack, C. J., Myskowski, P. L., Spleiss, O., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0333 · Cited by 218
Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh, S. J., Rizos, H., Scolyer, R. A., & Long, G. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.04.005 · Cited by 217
Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.02.004 · Cited by 215
Delord, J.-P., Robert, C., Nyakas, M., McArthur, G. A., Kudchakar, R., Mahipal, A., Yamada, Y., Sullivan, R., Arance, A., Kefford, R. F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2923 · Cited by 198
Development of encorafenib for BRAF-mutated advanced melanoma
Koelblinger, P., Thuerigen, O., & Dummer, R. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000426 · Cited by 177
Ultraviolet A and Photosensitivity during Vemurafenib Therapy
Dummer, R., Rinderknecht, J., & Goldinger, S. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1113752 · Cited by 166
Transient MEK inhibitor-associated retinopathy in metastatic melanoma
Urner-Bloch, U., Urner, M., Stieger, P., Galliker, N., Winterton, N., Zubel, A., Parseval, L. M., Dummer, R., & Goldinger, S. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu169 · Cited by 135
Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers
Subbiah, V., Puzanov, I. J., Blay, J., Chau, I., Lockhart, A. C., Raje, N. S., Wolf, J., Baselga, J. M., Meric‐Bernstam, F., Roszik, J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1265 · Cited by 133
Self-citationAnaplastic Thyroid Carcinoma, Version 2.2015
Haddad, R. I., Lydiatt, W. M., Ball, D. W., Busaidy, N. L., Byrd, D. R., Callender, G. G., Dickson, P. V., Duh, Q., Ehya, H., Haymart, M. R., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0139 · Cited by 122
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
Lin, L., Asthana, S., Chan, E., Bandyopadhyay, S., Martins, M. M., Olivas, V. R., Yan, J. J., Pham, L. Q., Wang, M. M., Bollag, G. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320956111 · Cited by 108
Effect of inhibition of the FGFR–MAPK signaling pathway on the development of ocular toxicities
van der Noll, R., Leijen, S., Neuteboom, G. H. G., Beijnen, J. H., & Schellens, J. H. M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.01.003 · Cited by 107
BRAF Mutations: Signaling, Epidemiology, and Clinical Experience in Multiple Malignancies
Hall, R. D., & Kudchadkar, R. R. (2014) · Cancer Control · doi:10.1177/107327481402100307 · Cited by 103
Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review
Guerra, A., Crescenzo, V. G. D., Garzi, A., Cinelli, M., Carlomagno, C., Tonacchera, M., Zeppa, P., & Vitale, M. (2013) · BMC Surgery · doi:10.1186/1471-2482-13-s2-s44 · Cited by 98
DAUD, A. I., & Tsai, K. K. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0456 · Cited by 97
Menzies, A. M., Ashworth, M. T., Swann, S., Kefford, R. F., Flaherty, K. T., Weber, J. S., Infante, J. R., Kim, K. B., Gonzalez, R. C., Hamid, O., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu529 · Cited by 90
Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors
Marusiak, A. A., Edwards, Z. C., Hugo, W., Trotter, E. W., Girotti, M. R., Stephenson, N. L., Kong, X., Gartside, M. G., Fawdar, S., Hudson, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms4901 · Cited by 88
Sandulache, V. C., Williams, M. D., Lai, S. Y., Lu, C., William, W. N., Busaidy, N. L., Cote, G. J., Singh, R. R., Luthra, R., & Cabanillas, M. E. (2016) · Thyroid · doi:10.1089/thy.2016.0076 · Cited by 84
BRAF, MEK and KIT inhibitors for melanoma: adverse events and their management.
Livingstone, E., Zimmer, L., Vaübel, J., & Schadendorf, D. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.03.03 · Cited by 82
Bronte, E., Bronte, G., Novo, G., Bronte, F., Bavetta, M. G., Re, G. L., Brancatelli, G., Bazan, V., Natoli, C., Novo, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5853 · Cited by 65
Planchard, D., Besse, B., Kim, T. M., Quoix, É., Souquet, P. J., Mazières, J., Barlési, F., Groen, H. J. M., Smit, E. F., Baik, C. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9075 · Cited by 47
Self-citationSchoenberger, S. D., & Kim, S. J. (2013) · Case Reports in Ophthalmological Medicine · doi:10.1155/2013/673796 · Cited by 46
Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations
Chatziandreou, I., Tsioli, P., Sakellariou, S., Mourkioti, I., Giannopoulou, I., Levidou, G., Korkolopoulou, P. A., Patsouris, E., & Saetta, A. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133859 · Cited by 44
van Dijk, E. H. C., Duits, D. E. M., Versluis, M., Luyten, G. P. M., Bergen, A. A. B., Kapiteijn, E., de Lange, M. J., Boon, C. J. F., & van der Velden, P. A. (2016) · Medicine · doi:10.1097/md.0000000000003457 · Cited by 43
Cohn, A. L., Day, B.-M., Abhyankar, S. S., Mckenna, E. F., Riehl, T., & Puzanov, I. J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s120440 · Cited by 41
Atkinson, V. G., Long, G. V., Menzies, A. M., McArthur, G. A., Carlino, M. S., Millward, M., Roberts‐Thomson, R., Brady, B., Kefford, R. F., Haydon, A. M., et al. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12656 · Cited by 32
BRAF‐V600 mutational status affects recurrence patterns of melanoma brain metastasis
Maxwell, R., Garzón-Muvdi, T., Lipson, E. J., Sharfman, W. H., Bettegowda, C., Redmond, K. J., Kleinberg, L. R., Ye, X., & Lim, M. K. (2016) · International Journal of Cancer · doi:10.1002/ijc.30241 · Cited by 31
Penna, I., Molla, A., Grazia, G., Cleris, L., Nicolini, G., Perrone, F., Picciani, B., Vecchio, M. D., de Braud, F., Mortarini, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6600 · Cited by 30
Wheler, J. J., Yelensky, R., Falchook, G. S., Kim, K. B., Hwu, P., Tsimberidou, A. M., Stephens, P. J., Hong, D. S., Cronin, M. T., & Kurzrock, R. (2015) · BMC Cancer · doi:10.1186/s12885-015-1029-z · Cited by 29
Sen, S., Meric‐Bernstam, F., Hong, D. S., Hess, K. R., & Subbiah, V. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx094 · Cited by 24
Self-citationSubbiah, V., Sen, S., Hess, K. R., Jankú, F., Hong, D. S., Khatua, S., Karp, D. D., Munoz, J., Falchook, G. S., Groisberg, R., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00189 · Cited by 23
Self-citationKeam, B., Kreitman, R. J., Wainberg, Z. A., Cabanillas, M. E., Cho, D. C., Italiano, A., Stein, A., Cho, J. Y., Schellens, J. H. M., Wen, P. Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy302.002 · Cited by 21
Self-citationRubin, K. M. (2017) · Clinical journal of oncology nursing · doi:10.1188/17.cjon.699-709 · Cited by 15
Cox, D. S., Allred, A. J., Zhou, Y., Infante, J. R., Gordon, M. S., Bendell, J. C., Jones, S. F., Burris, H. A., & Orford, K. W. (2014) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.152 · Cited by 13
Subbiah, V., Gervais, R., Riely, G. J., Hollebecque, A., Blay, J., Felip, E., Schüler, M., Gonçalvès, A., Italiano, A., Keedy, V. L., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.9074 · Cited by 12
Self-citation
Cited by
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02075-w · Cited by 341
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Plana, D., Palmer, A. C., & Sorger, P. K. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0212 · Cited by 307
Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas
Mudianto, T., Campbell, K. M., Webb, J., Zolkind, P., Skidmore, Z. L., Riley, R., Barnell, E. K., Ozgenc, I., Giri, T., Dunn, G. P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4179 · Cited by 33
Metadata
- Authors
- Subbiah, V., Baik, C., & Kirkwood, J. M.
- Venue
- Trends in Cancer
- Publisher
- Elsevier BV
- Published
- 2020-09
- Volume
- 6
- Issue
- 9
- Pages
- 797-810
- ISSN
- 2405-8025 (ISSN-L)
- 2405-8033
- OpenAlex
- W3034783173
- Cited by
- 344
- References
- 93
- FWCI
- 3.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.